Peptide Therapy for Dogs & Cats — Veterinary Applications Guide

Peptide therapy is not new to veterinary medicine. Adequan, a polysulfated glycosaminoglycan injectable, received FDA approval for canine osteoarthritis in 1997. What is new is the growing interest in off-label and experimental peptides — BPC-157 for post-surgical recovery, TB-500 for tendon injuries in performance horses, thymosin alpha-1 for immune modulation in chronically ill cats. Some of these applications rest on solid evidence. Others are extrapolated from rodent studies with no controlled veterinary trials behind them. This guide separates the two.

Adequan (Polysulfated Glycosaminoglycan) — The Gold Standard

Adequan Canine is the only FDA-approved injectable disease-modifying osteoarthritis drug (DMOAD) for dogs in the United States, carrying NADA 141-038 approval since July 1997. It is not technically a peptide — it is a semi-synthetic glycosaminoglycan extracted from bovine tracheal cartilage — but it occupies the same therapeutic space and is frequently discussed alongside veterinary peptide protocols.

How it works

Adequan inhibits cartilage-degrading enzymes (specifically, serine proteases and metalloproteinases that break down proteoglycans), stimulates synthesis of new cartilage matrix components, improves synovial fluid viscosity, and reduces inflammatory mediators within the joint capsule. Unlike oral joint supplements such as glucosamine and chondroitin, Adequan reaches the joint at pharmacologically relevant concentrations because it bypasses the gastrointestinal tract entirely.

Dosing protocol

The FDA-approved protocol for dogs is 4.4 mg/kg (2 mg/lb) administered by intramuscular injection twice weekly for four weeks, totaling eight injections. Many veterinarians follow this loading phase with maintenance injections at monthly or bimonthly intervals, though maintenance dosing has not been formally studied in controlled trials.

For cats, Adequan is used off-label. Published veterinary references suggest doses of 5 to 10 mg per cat by intramuscular or subcutaneous injection, though standardization is lacking. In horses, the approved Adequan Equine protocol is 500 mg IM every four days for 28 days, or 250 mg by intra-articular injection once weekly for five weeks.

Safety profile

In the pivotal clinical trial, adverse reactions were reported after roughly 2% of injections and included transient injection-site pain, brief diarrhea episodes, and one incident of abnormal bleeding. Because PSGAG has mild anticoagulant properties, it should be used with caution in animals with bleeding disorders or those receiving concurrent anticoagulant therapy.

Evidence quality: Strong

This is an FDA-approved drug with published clinical efficacy data and decades of veterinary clinical use. It is the benchmark against which experimental veterinary peptide therapies should be measured.

BPC-157 in Veterinary Medicine

Body Protection Compound-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence found in human gastric juice. In rodent models, it has demonstrated accelerated healing of tendons, ligaments, muscles, the GI tract, and bone. A 2025 systematic review published in the Orthopaedic Journal of Sports Medicine (Vasireddi et al.) screened 544 articles and confirmed consistent pro-angiogenic effects and enhanced growth hormone receptor expression across preclinical musculoskeletal injury models.

Canine applications

Veterinarians working in integrative and sports medicine have begun using BPC-157 in dogs recovering from cranial cruciate ligament (CCL) rupture repair, patellar luxation surgery, tendon injuries, and muscle strains. A comprehensive safety study (Sikiric et al., 2020 review) reported no lethal dose identified in dogs, no genotoxicity, and no teratogenicity. This is encouraging from a safety standpoint but does not constitute efficacy evidence.

The critical gap: no randomized, controlled clinical trials of BPC-157 have been published in dogs. The canine applications are extrapolated from rodent data and uncontrolled clinical observations. Veterinarians using BPC-157 in dogs are operating on biological plausibility, not proven veterinary efficacy.

Typical veterinary dosing

Dosing in dogs is not standardized. Published protocols from integrative veterinary practitioners typically range from 5 to 10 mcg/kg administered subcutaneously once daily, with treatment courses of 2 to 4 weeks. Some practitioners use higher loading doses in the immediate post-surgical period. These are empirical doses extrapolated from rodent studies — they have not been validated in pharmacokinetic studies in dogs.

Evidence quality: Preliminary

Strong preclinical data. Good safety profile in toxicology studies. Zero controlled veterinary clinical trials. Use in dogs is experimental and should only be undertaken with direct veterinary oversight.

TB-500 (Thymosin Beta-4 Fragment) — Equine and Canine Tissue Repair

TB-500 is a synthetic fragment of thymosin beta-4, a 43-amino acid peptide found in virtually all mammalian cells. Thymosin beta-4 is the primary intracellular G-actin sequestering peptide and plays a central role in cell migration, angiogenesis, and wound healing. TB-500 replicates the active region responsible for actin binding and upregulation.

Mechanism of action

TB-500 promotes tissue repair through several pathways: upregulation of actin (essential for cell structure and motility), promotion of cell migration to injury sites, stimulation of new blood vessel formation, regulation of inflammatory responses, and promotion of organized collagen deposition. Histological studies suggest TB-500 promotes more structurally sound repair tissue rather than disordered scar formation — a meaningful distinction for tendons and ligaments where biomechanical function matters.

Equine medicine

Equine sports medicine has provided the most extensive clinical experience with TB-500. Veterinarians treating performance horses — particularly thoroughbred racehorses — have used it for superficial digital flexor tendon injuries, suspensory ligament desmitis, and joint capsule inflammation. Several uncontrolled veterinary case series report meaningful clinical improvement, reduced lameness scores, and ultrasound evidence of improved tendon architecture.

However, the equine evidence base consists largely of clinical observations rather than randomized trials. Published equine pharmacokinetic data indicate that BPC-157 — and likely TB-500 as well — is detectable in urine at very low concentrations (0.01 ng/mL) with an extended withdrawal period of 30 or more days, which matters for competition horses subject to drug testing.

Canine applications

TB-500 use in dogs follows a similar pattern to BPC-157: extrapolation from the equine and rodent literature, not controlled canine studies. Veterinarians using it in dogs typically target post-surgical recovery, chronic tendinopathies, and soft tissue injuries. Subcutaneous dosing ranges reported by integrative practitioners are typically 0.1 to 0.25 mg per kg of body weight, administered twice weekly during an initial loading phase, then reduced to weekly or biweekly maintenance.

Evidence quality: Preliminary

Compelling biological mechanism. Reasonable equine clinical experience (uncontrolled). No controlled canine trials. Competition horses must observe withdrawal periods. Off-label and experimental in all small animal applications.

Thymosin Alpha-1 — Immune Modulation in Cats and Dogs

Thymosin alpha-1 is a 28-amino acid peptide fragment of prothymosin alpha, naturally produced by the thymus gland. It is an immunomodulator — not an immune stimulant — meaning it helps calibrate immune responses rather than simply amplifying them. In humans, it is approved in over 35 countries (marketed as Zadaxin) for hepatitis B and C, and has been studied as an adjunct in cancer immunotherapy and severe infections.

Feline applications

Thymosin alpha-1 has attracted attention in feline medicine for its potential role in supporting immune function in cats with chronic viral infections and immune-mediated diseases. While feline infectious peritonitis (FIP) treatment has been transformed by the antiviral GS-441524 — now available in the US as a compounded veterinary formulation since mid-2024 — thymosin alpha-1 has been explored as an adjunctive immunomodulator in cats with FIP, feline leukemia virus (FeLV), and feline immunodeficiency virus (FIV).

The rationale is straightforward: thymosin alpha-1 enhances T-cell maturation, promotes dendritic cell function, and helps balance Th1/Th2 immune responses. In cats with viral-induced immune suppression, these properties could theoretically support recovery when combined with direct antiviral therapy. However, controlled feline clinical trials are lacking. Most reports are anecdotal or from small, uncontrolled case series.

Canine applications

In dogs, thymosin alpha-1 has been explored for chronic infections, post-surgical immune support, and as an adjunct in cancer treatment protocols. Veterinary oncologists investigating immunomodulatory approaches have expressed interest in thymosin alpha-1 as a complement to conventional chemotherapy, though published canine data remains sparse.

Equine use

Thymosin alpha-1 sees its most established veterinary use in horses, where practitioners prescribe it for recurrent infections, immune challenges during intensive training or transport, and as supportive care during periods of physiological stress. Equine dosing protocols are better documented than canine or feline, though still largely empirical.

Evidence quality: Moderate to preliminary

Strong immunological rationale supported by decades of human clinical data. Established use in equine practice. Feline and canine use is logical but lacks controlled veterinary trials. Best understood as an adjunctive tool rather than a standalone therapy.

Dosing Considerations Across Species

One of the most dangerous assumptions in veterinary peptide therapy is that human doses can be directly scaled to animals by body weight. Pharmacokinetics differ substantially across species. Metabolic rate scales allometrically — a 5-kg cat has a much higher metabolic rate per kilogram than a 40-kg dog, which in turn differs from a 500-kg horse. Absorption rates, protein binding, half-life, and renal clearance all vary.

General principles

Allometric scaling is the standard method for interspecies dose conversion. A common approach uses the formula: animal dose = human dose multiplied by (animal weight / human weight) raised to the 0.75 power. This accounts for the non-linear relationship between body mass and metabolic rate. However, allometric scaling provides only a starting estimate. Species-specific pharmacokinetic data, when available, should always take precedence.

Smaller animals require relatively higher doses per kilogram. A cat will generally need a higher mg/kg dose than a dog to achieve equivalent plasma concentrations, and both will need higher per-kg doses than a horse. This is counterintuitive to many pet owners but is a basic pharmacological principle.

Route of administration matters. Subcutaneous injection is the most common route for peptide administration in companion animals. Intramuscular injection (used for Adequan) provides faster absorption. Oral peptide administration is generally impractical in veterinary medicine due to proteolytic degradation, though pentosan polysulfate has shown some oral bioavailability in canine studies.

Frequency adjustments. Animals with higher metabolic rates may require more frequent dosing to maintain therapeutic levels. A twice-daily protocol in a small dog may be pharmacologically equivalent to a once-daily protocol in a large breed.

The Regulatory Landscape for Veterinary Peptides

The regulatory status of veterinary peptides is complex and evolving, particularly in the United States.

FDA-approved veterinary peptides

Only a handful of peptide-class drugs hold FDA approval for veterinary use. Adequan Canine and Adequan Equine are the most prominent. GnRH agonists (deslorelin, used in reproductive management) and certain synthetic hormone analogs also fall into this category.

Veterinary compounding

In the United States, veterinary compounding is governed by the Animal Drug Compounding from Bulk Substance rules under section 512(a)(5) of the Federal Food, Drug, and Cosmetic Act, as well as state veterinary practice acts. Compounding pharmacies may prepare peptide formulations for individual animals under the supervision of a licensed veterinarian with a valid veterinarian-client-patient relationship (VCPR).

The FDA's two-category classification system for bulk drug substances affects veterinary compounding. Category 1 substances have sufficient supporting safety information and may be compounded while under FDA review. Category 2 substances carry unresolved safety concerns and are generally ineligible for routine compounding. In late 2023, the FDA moved 19 peptides — including BPC-157 — from Category 1 to Category 2, restricting their compounding availability.

2026 regulatory shifts

In February 2026, HHS Secretary Robert F. Kennedy Jr. announced efforts to move 14 of the 19 restricted peptides back to Category 1, with formal review by the FDA's Pharmacy Compounding Advisory Committee scheduled for July 2026. If enacted, this would significantly expand legal compounding access to peptides like BPC-157 for both human and veterinary use. However, as of June 2026, final regulatory action has not been completed, and the legal status remains in flux.

Extra-label use

Licensed veterinarians may prescribe FDA-approved human drugs for extra-label use in animals under the Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994, provided there is a valid VCPR, no approved veterinary drug is available for the condition, and the animal is not a food-producing species (or specific withdrawal periods are observed). This provides a legal pathway for some peptides approved for human use in other countries.

Working With Your Veterinarian

This section is not a formality. Veterinary peptide therapy, outside of FDA-approved products like Adequan, is genuinely experimental. The dosing is empirical. The evidence is preclinical or uncontrolled. Species-specific pharmacokinetics are poorly characterized for most peptides.

A qualified veterinarian can evaluate whether peptide therapy is appropriate for your animal's condition, ensure proper reconstitution and sterile administration technique, monitor for adverse reactions (particularly with immunomodulatory peptides where over- or under-stimulation of immune function is possible), adjust dosing based on clinical response, and integrate peptide therapy with proven conventional treatments rather than using it as a replacement.

Pet owners who source peptides independently and administer them without veterinary guidance risk incorrect dosing, contaminated products (veterinary-grade peptide sourcing is poorly regulated), missed diagnoses, and adverse interactions with other medications.

Practical Takeaways

What has strong evidence: Adequan (PSGAG) for canine osteoarthritis is FDA-approved, well-studied, and effective. If your dog has degenerative joint disease, ask your veterinarian about it.

What has promising but incomplete evidence: BPC-157 and TB-500 for post-surgical and soft tissue healing have strong preclinical data and reasonable safety profiles, but lack controlled veterinary trials. Their use in companion animals is experimental and should be supervised by a veterinarian experienced with these protocols.

What has a sound rationale but limited veterinary data: Thymosin alpha-1 for immune modulation in cats with chronic viral infections or in dogs undergoing cancer treatment has decades of human clinical evidence supporting its immunological mechanism, but feline and canine clinical data is sparse.

What you should always do: Work with a licensed veterinarian who has experience with integrative or regenerative medicine protocols. Do not extrapolate human dosing to animals without professional guidance. Source peptides from compounding pharmacies operating under veterinary oversight, not from unregulated suppliers. Treat peptide therapy as complementary to — not a replacement for — conventional veterinary care.

The veterinary peptide landscape is moving fast. Regulatory changes in 2026 may expand access. New clinical data from equine and canine studies is accumulating. But the current reality is that most veterinary peptide use outside of Adequan operates in a grey zone between biological plausibility and clinical proof. Informed skepticism, combined with proper veterinary supervision, is the appropriate stance.